Clinical Trials Logo

Impulse Control Disorders clinical trials

View clinical trials related to Impulse Control Disorders.

Filter by:

NCT ID: NCT03970239 Recruiting - Parkinson Disease Clinical Trials

Serotonin in Impulse Control Disorders in Parkinson's Disease

Park-IMPULSE
Start date: May 13, 2019
Phase: N/A
Study type: Interventional

Impulse control disorders are frequent and troublesome in patients with Parkinson's disease. However, the cerebral functional alterations related to impulse control disorders in Parkinson's disease are poorly understood and may involve the serotoninergic system besides alterations in the dopaminergic system. The primary objective of this study is to investigate the cerebral functional alterations in the serotoninergic system in patients with Parkinson's disease and impulse control disorders using Positron Emission Tomography with highly specific radiotracers of serotonin transporter (SERT) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and of serotonin 5-Hydroxytryptamine 2A (5-HT2A) receptor using [18 Fluorine]-altanserin ([18F]-altanserin), in comparison to patients with Parkinson's disease without impulse control disorders and healthy volunteers.

NCT ID: NCT03887429 Completed - Clinical trials for Impulse Control Disorders

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Start date: March 4, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.

NCT ID: NCT02934919 Not yet recruiting - Parkinson Disease Clinical Trials

Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study

Nalmefene TCI
Start date: December 2016
Phase: Phase 2
Study type: Interventional

Impulse control disorders (ICDs) (such as pathological gambling, hypersexuality, compulsive shopping …) are an increasingly recognized psychiatric complications in Parkinson's disease (PD). Therapeutic management of these disorders is important since they have an impact on patient quality of life. Dopamine agonists play a key role in the emergence of ICD. Animal models and imaging underline the implication of opioid system in the genesis of ICD. An opioid antagonist, the naltrexone, has been studied to treat ICDs in PD. Papay and al 2014 have found that patients treated by naltrexone showed an interesting decrease of their ICDs measured by the QUIP RScale. Nevertheless, naltrexone has shown adverse effects such as increasing hepatic liver enzymes. Nalmefene has no known hepatic adverse effects. Nalmefene is an opioid antagonist that has an antagonist action on μ and δ receptors, but also an agonist action on κ receptor. Grant and al 2006 has shown significant reduction of the severity of pathological gambling in patients treated with nalmefene. The primary purpose is to evaluate the efficacy and the safety of nalmefene in the treatment of ICDs in PD.

NCT ID: NCT02796040 Recruiting - Parkinson's Disease Clinical Trials

Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.

TCI-IRMdiff
Start date: February 2016
Phase: N/A
Study type: Interventional

Impulse control disorders (ICD) are frequent in Parkinson's Disease. Neurobiological substrates of these symptoms are largely unknown. The investigators aim to explore mesocorticolimbic pathway in Parkinson's disease patients with impulse control disorders (ICD) using an MRI technique called tensor diffusion imaging (DTI). More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD. Secondary objectives are to demonstrate a difference in volume of VTA, in FA in others structures included in reward system (prefrontal cortex, nucleus accumbens, amygdala), and in number of fibers between VTA and the other structures of reward system between this two groups. Other objective is to measure and compare these same variables between Parkinson's patients and healthy controls. We hypothesized that a denervation of mesocorticolimbic pathway predisposes Parkinson's patients to ICD.

NCT ID: NCT02755181 Completed - Clinical trials for Borderline Personality Disorder

fMRI in Impulsivity

Start date: July 22, 2016
Phase:
Study type: Observational

This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.

NCT ID: NCT02733562 Completed - Obesity Clinical Trials

Results of Sleeve Gastrectomy Surgery in Relation With Eating Habits (After One Year)

Behavior
Start date: January 2014
Phase: N/A
Study type: Observational

Sleeve gastrectomy is one of the most common surgical procedures performed today for patients that undergo bariatric surgery. One of the primary reasons for morbid obesity is unhealthy eating habits and the belief that changes in those habits can ensure the success. Objectives: The investigators aimed to explore the effect of different eating habits prior to the bariatric surgery on the surgery success and on different aspect of quality of life. Design: The investigators conducted this study on patients that underwent sleeve gastrectomy as the first bariatric operation.

NCT ID: NCT02722174 Completed - Clinical trials for Impulse Control Disorders

Fingerprinting of Impulsivity

Start date: July 22, 2016
Phase:
Study type: Observational

The study aims to examine a battery of behavioral and questionnaire measures in 4 disorders clinically associated with impulsivity and in health controls, to: 1) investigate if the different populations have a distinct behavioral profile, and 2) to investigate if there are specific measures that are reliable and sensitive measures of impulsivity across diagnoses.

NCT ID: NCT02319395 Completed - Parkinson Disease Clinical Trials

Behavioural Addiction and Genetics in Parkinson's Disease

BADGE-PD
Start date: November 2011
Phase: N/A
Study type: Observational

The " Behavioural Addiction and Genetics in Parkinson's Disease " study (BADGE-PD) is a national (France), multicenter, genetic association, case-control study to identify genetic factors associated with behavioural addiction (or Impulse Control Disorders, ICD) related to dopamine agonists treatment in Parkinson's disease (PD). Polymorphisms of candidate genes supposed to be involved in this adverse effect will be compared in 200 PD patients with ICD (n=200) and 200 matched PD patients without ICD (n=200).

NCT ID: NCT01354236 Enrolling by invitation - Anxiety Disorders Clinical Trials

Mental Health Related to School Dropout in Luxembourg

Start date: January 2011
Phase: N/A
Study type: Observational

This study aims to investigate psychosocial risk- and protective factors such as psychiatric disorder, socio-economic background and family functioning among school dropouts and to compare the findings with those by a matched control group of regularly enrolled students.

NCT ID: NCT01052831 Completed - Parkinson Disease Clinical Trials

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Start date: November 2009
Phase: Phase 4
Study type: Interventional

This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.